We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
DPH.LSE

Price
-
Stock movement up
+- (%)
Company name
Dechra Pharmaceuticals PLC
Exchange
(LSE
,
Currency
GBX
)
Sector
Healthcare >
Drug Manufacturers - General
Market cap
440.36B
Ent value
441.10B
Price/Sales
578.28
Price/Book
583.10
Div yield
-
Div growth
-
Growth years
-
FCF payout
-25850.00%
Trailing P/E
-
Forward P/E
26.19
PEG
-
EPS growth
-
1 year return
29.82%
3 year return
2.39%
5 year return
9.61%
10 year return
18.60%
Last updated: 2024-12-17

DIVIDENDS

DPH.LSE does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF6923.91
Price to FCF-
Price to EBITDA38969.96
EV to EBITDA39035.43

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales578.28
Price to Book583.10
EV to Sales579.25

FINANCIALS

Per share

Loading...
Per share data
Current share count113.91M
EPS (TTM)-0.24
FCF per share (TTM)-0.00

Income statement

Loading...
Income statement data
Revenue (TTM)761.50M
Gross profit (TTM)429.60M
Operating income (TTM)17.10M
Net income (TTM)-27.90M
EPS (TTM)-0.24
EPS (1y forward)147.64

Margins

Loading...
Margins data
Gross margin (TTM)56.41%
Operating margin (TTM)2.25%
Profit margin (TTM)-3.66%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash74.40M
Net receivables161.90M
Total current assets467.90M
Goodwill334.50M
Intangible assets587.90M
Property, plant and equipment224.70M
Total assets1.57B
Accounts payable144.50M
Short/Current long term debt504.50M
Total current liabilities164.00M
Total liabilities814.20M
Shareholder's equity755.20M
Net tangible assets-162.10M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)63.60M
Capital expenditures (TTM)22.80M
Free cash flow (TTM)-200.00K
Dividends paid (TTM)51.70M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-3.69%
Return on Assets-1.78%
Return on Invested Capital-2.24%
Cash Return on Invested Capital-0.02%

STOCK INFORMATION

Downside potential

Loading...
Downside potential data
DPH.LSES&P500
Current price drop from All-time high-28.47%-0.58%
Highest price drop-79.21%-56.47%
Date of highest drop6 Mar 20039 Mar 2009
Avg drop from high-15.73%-11.07%
Avg time to new high18 days12 days
Max time to new high1078 days1805 days
COMPANY DETAILS
DPH.LSE (Dechra Pharmaceuticals PLC) company logo
Marketcap
440.36B
Marketcap category
Large-cap
Description
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom. As of January 16, 2024, Dechra Pharmaceuticals PLC was taken private.
Employees
2457
Investor relations
-
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found